Clear cell (ccRCC) constitutes nearly 70% of all cases and is characterized by inactivating mutations in the von Hippell–Lindau gene (VHL), which encodes the VHL protein, a critical component in the targeting of the transcription factor hypoxia-inducible factor (HIF) for degradation. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.